Frequently Asked Questions
The market is segmented based on , By Product (Left Ventricular Assist Devices (LVADs), Right Ventricular Assist Devices (RVADs), Biventricular Assist Devices (BIVADs), Percutaneous Ventricular Assist Devices (PVADs), Total Artificial Heart (TAH)), Application (Destination Therapy, Bridge-to-Candidacy (BTC) Therapy, Bridge-to-Transplant (BTT) Therapy, Bridge-to-Recovery (BTR) Therapy, Others), Age (Below 18 Years, 19-39 Years, 40-59 Years, 60-79 Years, Above 80 Years), Flow (Pulsatile Flow, Continuous Flow), Design (Transcutaneous, Implantable), Technology (Magnetic, Hydrodynamic Levitation) – Industry Trends and Forecast to 2030.
.
The Global Third Generation Ventricular Assist Devices Market size was valued at USD 2.50 USD Billion in 2022.
The Global Third Generation Ventricular Assist Devices Market is projected to grow at a CAGR of 17.5% during the forecast period of 2023 to 2030.
The major players operating in the market include ABIOMED , Asahi Kasei Corporation , Abbott , Calon Cardio , Jarvik HeartInc. , Medtronic , Terumo Corporation , BiVACOR Inc. , Cardiobridge GmbH , CHF SolutionsInc. , EvaheartInc. , LivaNova PLC CorWave SA , Fresenius Medical Care AG & Co. KGaA , MiTiHeart Corporation , Getinge AB , SynCardia SystemsLLC , Teleflex Incorporated , Mayo Foundation for Medical Education and Research .
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
